A behavioral health program dramatically reduces drug costs despite increasing utilization.
A physician prescribed Sprycel® to treat a patient with chronic myelogenous leukemia (CML). Spycel is classified as a specialty medication and costs $14,542 for a 30-day supply.
Our PharmD researched therapeutic alternatives and discovered that according to National Comprehensive Cancer Network (NCCN) guidelines, Imatinib (generic Gleevec) is also classified as Category 1 treatment for patients with low-risk CML. IPM then notified the prescriber who agreed with the recommendation to switch to Imatinib 400 mg daily at a cost of $7,917 for a 30-day supply.
While equally effective as Sprycel, Imatinib is less expensive and saved the employer $6,625 per month or $79,500 annually.